A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Simmitinib Plus SG001 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06132217
• Other study ID #: HA1818-003
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: January 30, 2024
• Est. completion date: January 30, 2027

Study information

• Verified date: November 2023
• Source: Shanghai Runshi Pharmaceutical Technology Co., Ltd
• Contact: Clinical Trials Information Group officer
• Phone: 86-0311-69085587
• Email: ctr-contact[@]cspc.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 168
• Est. completion date: January 30, 2027
• Est. primary completion date: January 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Have fully understood and voluntarily sign the ICF for this study;

2. Age of 18-75 years (inclusive);

3. Dose escalation phase: patients with histologically or cytologically confirmed inoperable or metastatic advanced solid tumors;

4. Dose expansion phase: patients who have failed standard treatment (PD or intolerable toxicity after treatment), have no available standard treatment.According to the previous data, the specific tumor cohort was expanded.

5. In the expansion phase, patients should agree to provide tissue specimens for detection of PD-L1 expression levels and/or MSI or dMMR status;

6. At least one measurable lesion according to RECIST 1.1;

7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1;

8. Adequate organ function, defined as:

Neutrophil count (ANC) = 1.5 × 10^9/L; Platelet count (PLT) = 100× 10^9/L; Hemoglobin (Hb) = 90 g/L; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × upper limit of normal (ULN) (= 5.0 × ULN for patients with liver metastases); Serum total bilirubin (TBIL) = 1.5 × ULN; Serum creatinine = 1.5 × ULN; Prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio(INR)=1.5 × ULN; Thyroid Stimulating Hormone (TSH)=ULN; Left ventricular ejection fraction (LVEF)=50%; Male and female patients of childbearing age must agree to take effective contraceptive measures during treatment and within 6 months after the last dose of treatment.

Exclusion Criteria:

1. Patients who have previously received any anti-tumor therapy within 4 weeks prior to the first dose;

2. Urine protein = ++ and 24 h urine protein > 1.0g at screening period;

3. Symptomatic central nervous system (CNS) metastases or meningeal metastases;

4. Patients who have previously received any live attenuated vaccine within 4 weeks before the first use of the study treatment or are expected to received any live attenuated vaccine during the study;

5. History of allergic reactions attributed to any monoclonal antibody, and uncontrolled history of allergic asthma;

6. Patients with other types of malignant tumors within 5 years prior to the screening, except for radically resected, non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ, or other carcinoma in situ;

7. Patients with any active autoimmune disease requiring systemic therapy within 2 years prior to the first dose;

8. Patients with bleeding tendency; active bleeding or a history of heavy bleeding within the past 6 months;

9. Presence of any severe and/or uncontrolled disease before starting treatment;

10. Any active infection requiring antibiotics or hormones systemic treatment by intravenous infusion within 14 days prior to the first dose;

11. Dose expansion phase: Prior systemic therapy with immunosuppressants or immunoagonists targeting PD-1, PD-L1, CTLA-4, etc;

12. Dose expansion phase: Prior systemic therapy with Antiangiogenic drugs including Anlotinib, Afatinib , Lenvatinib, Sorafenib and Fruquintinib, etc;

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• Simmitinib
Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
• SG001
Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Locations

Country	Name	City	State
China	Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Escalation Phase: Dose Limited Toxicity (DLT)		From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
Primary	Dose Escalation Phase: Maximum Tolerated Dose (MTD)		From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
Primary	Dose Escalation Phase: Recommended Phase 2 Dose (RP2D)		From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
Primary	Dose Escalation Phase-Incidence rate of Adverse Event (AE).		From first dose to 30 days post the last dose, with approximately 3 years
Primary	Dose Expansion Phase - Objective Response Rate (ORR) evaluated by Independent Review Committee (IRC) or investigators in advanced solid tumor based on RECIST 1.1.		Up to approximately 3 years.
Secondary	Plasma Concentration of simmitinib .		Up to approximately 3 years.
Secondary	Plasma Concentration of SG001		Up to approximately 3 years.
Secondary	Immunogenicity Assessments for Anti-drug Antibody		Up to approximately 3 years.
Secondary	Dose Escalation Phase: ORR		Up to approximately 3 years.
Secondary	Disease Control Rate (DCR)		Up to approximately 3 years.
Secondary	Progression-free Survival (PFS)		Up to approximately 3 years.
Secondary	Overall Survival (OS)		Up to approximately 3 years.
Secondary	Duration of Objective Response (DOR)		Up to Approximately 3 years.